Wave Life Sciences (WVE) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares.
View WVE analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12 month price targets for Wave Life Sciences' stock. Their WVE share price forecasts range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.

Wave Life Sciences' stock was trading at $7.00 at the start of the year. Since then, WVE stock has decreased by 47.7% and is now trading at $3.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our WVE earnings forecast.

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its earnings results on Wednesday, March, 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.05. The firm had revenue of $1.24 million for the quarter, compared to the consensus estimate of $2.35 million. Wave Life Sciences had a negative net margin of 1,021.14% and a negative trailing twelve-month return on equity of 1,038.84%.

ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and Invesco Nasdaq Biotechnology ETF (IBBQ).

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (6.71%), BlackRock Inc. (1.43%), FMR LLC (1.05%), Geode Capital Management LLC (0.70%), Bank of America Corp DE (0.58%) and Platinum Investment Management Ltd. (0.46%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends.

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WVE stock can currently be purchased for approximately $3.66.

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $360.04 million and generates $14.83 million in revenue each year. The company earns $-161,820,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

The company employs 235 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.